Companies › Deciphera Pharmaceuticals
5 active drug programs in 11 registered trials: 7 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Other, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vimseltinib (DCC-3014) KIT/PDGFRA/CSF1R inhibitor | CSF1R, KIT, PDGFRA | Phase 3 | Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants … | Dec 2026 |
| Ripretinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 3 | GIST; Gastrointestinal Stromal Tumors | Mar 2027 |
| Inlexisertib (DCC-3116) Protein kinase C (PKC) inhibitor | PKC | Phase 1 | GIST | Mar 2027 |
| DCC-3009 Tyrosine kinase inhibitor | – | Phase 1 | Gastrointestinal Stromal Tumor (GIST) | May 2028 |
| DCC-2812 GCN2 activator | GCN2 | Phase 1 | Renal Cell Carcinoma | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07539090 | Vimseltinib (DCC-3014) | Phase 1 | Healthy Participants | Other | Oct 2026 |
| NCT07744802 | Vimseltinib (DCC-3014) | Phase 1 | Healthy Male Participants | Other | Dec 2026 |
| NCT05957367 | Ripretinib | Phase 1 | GIST | Oncology | Mar 2027 |
| NCT05957367 | Inlexisertib (DCC-3116) | Phase 1 | GIST | Oncology | Mar 2027 |
| NCT05734105 | Ripretinib | Phase 3 | GIST | Oncology | Dec 2027 |
| NCT03673501 | Ripretinib | Phase 3 | Gastrointestinal Stromal Tumors | Oncology | Dec 2027 |
| NCT06630234 | DCC-3009 | Phase 1 | Gastrointestinal Stromal Tumor (GIST) | Oncology | May 2028 |
| NCT05059262 | Vimseltinib (DCC-3014) | Phase 3 | Tenosynovial Giant Cell Tumor | Oncology | Jul 2028 |
| NCT03069469 | Vimseltinib (DCC-3014) | Phase 1 | Advanced Malignant Neoplasm | Oncology | Aug 2028 |
| NCT06966024 | DCC-2812 | Phase 1 | Renal Cell Carcinoma | Oncology | Feb 2029 |
| NCT06619561 | Vimseltinib (DCC-3014) | Phase 2 | Chronic Graft-Versus-Host Disease (cGVHD) | Respiratory | Oct 2029 |
Blueprint Medicines Cogent Biosciences Jiangsu Alphamab Biopharmaceuticals Abbisko Therapeutics Pierre Fabre Medicament
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.